ANNEXON, INC.
ANX005, a monoclonal antibody therapeutic that inhibits C1q to prevent synapse loss in Alzheimer's disease
- Sector
- Biotech
- Headquarters
- Brisbane, CA
- Founded
- 2011
- Latest Form D
- $130M, Jul 2022
- Total capital
- $280M
- Federal grants
- $1.2M
- 1 award · 2016
- Rank in peer group#252 of 326
- Private capital raised
- $278M
- 4 Form D · last Jul 2022
- 51 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 14
- 26 pending · first 2017
- Rank in peer group#19 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$130M
- Private capital raisedForm D · SEC · 3rd filing$102M
- Private capital raisedForm D · SEC · 2nd filing$45M
- Federal grantHealth and Human S · Phase II · Development of novel inhibitors of C1q for the treatment of Neurodegenerative diseases$1.2M
- Private capital raisedForm D · SEC · 1st filing$1.0M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#19 · top 6%
- Linked publications#10 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Arnon RosenthalResearcherDirectorLinked by 1 patent
- Ted L YednockResearcherExecutive OfficerLinked by 1 patent · $1.2M in grants as PI
- Ben BarresDirectorNamed in SEC Form D filings
- Bettina M. Cockroft, M.D.DirectorNamed in SEC Form D filings
- Campbell L MurrayDirectorNamed in SEC Form D filings
- Carol L GallagherDirectorNamed in SEC Form D filings
Show all 21 people
- Douglas LoveExecutive Officer, DirectorNamed in SEC Form D filings
- Emmett E. CunninghamDirectorNamed in SEC Form D filings
- Jennifer LewExecutive OfficerNamed in SEC Form D filings
- Jung E. ChoiDirectorNamed in SEC Form D filings
- Larry C. Mattheakis, Ph.DExecutive OfficerNamed in SEC Form D filings
- Mark L SmithExecutive OfficerNamed in SEC Form D filings
- Michael C. OverdorfExecutive OfficerNamed in SEC Form D filings
- Muneer L SatterDirectorNamed in SEC Form D filings
- Ricky A. SunDirectorNamed in SEC Form D filings
- Sanjay KeswaniExecutive OfficerNamed in SEC Form D filings
- Stacie WeningerDirectorNamed in SEC Form D filings
- Thomas G. WiggansDirectorNamed in SEC Form D filings
- William H. Carson, M.D.DirectorNamed in SEC Form D filings
- William D. WaddillDirectorNamed in SEC Form D filings
- William D. YoungDirectorNamed in SEC Form D filings
What it has protected
USPTO · 14 granted of 40- GrantedMethod Of Treating A Blood Disorder Associated With C1Q-MEDIATED Activation Of The Classical Complement Pathway By Administering An ANTI-C1Q AntibodyUSPTOUS 12,735,473
- PendingFormulations For ANTI-C1Q AntibodiesUSPTOApplication 19118600
- PendingInhibitors Of Complement Factors And Uses ThereofUSPTOApplication 19380232
Show all 40 patent records
- Method Of Treating A Blood Disorder Associated With C1Q-MEDIATED Activation Of The Classical Complement Pathway By Administering An ANTI-C1Q AntibodySep 15, 2026 · US 12,735,473Granted
- Formulations For ANTI-C1Q AntibodiesJul 9, 2026 · Application 19118600Pending
- Inhibitors Of Complement Factors And Uses ThereofJun 11, 2026 · Application 19380232Pending
- Inhibitors Of Complement Factors And Uses ThereofMar 12, 2026 · Application 19395200Pending
- Anti-complement Factor C1Q Antibodies And Uses ThereofJan 27, 2026 · US 12,534,522Granted
- Inhibitors Of Complement Factors And Uses ThereofJan 13, 2026 · US 12,522,619Granted
- Inhibitors Of Complement Factors And Uses ThereofDec 30, 2025 · US 12,509,474Granted
- Anti-complement Factor C1Q Antibodies With Single Binding Arms And Uses ThereofDec 2, 2025 · US 12,486,322Granted
- Compositions And Methods For Treating Ocular DiseasesOct 9, 2025 · Application 18860825Pending
- Compositions And Methods For Treating Lupus NephritisOct 9, 2025 · Application 18865443Pending
- Compositions And Methods For Treating Huntington’s DiseaseMar 6, 2025 · Application 18725580Pending
- Anti-complement Factor C1Q Fab Fragments And Uses ThereofJan 2, 2025 · Application 18680437Pending
- Anti-complement Factor C1Q Fab Fragments And Uses ThereofJun 4, 2024 · US 11,999,779Granted
- Compositions And Methods For Treating Blood DisordersApr 4, 2024 · Application 17769180Pending
- Compositions And Methods For Treating Ocular DiseasesFeb 22, 2024 · Application 18265380Pending
- Compositions And Methods For Treating EpilepsyFeb 1, 2024 · Application 17923456Pending
- Humanized Anti-complement Factor C1Q Antibodies And Uses ThereofJan 25, 2024 · Application 18100885Pending
- Method Of Treating A Blood Disorder Associated With C1Q-MEDIATED Activation Of The Classical Complement Pathway By Administering An ANTI-C1Q AntibodyDec 7, 2023 · Application 18032084Pending
- Inhibitors Of Complement Factors And Uses ThereofNov 14, 2023 · US 11,814,404Granted
- Anti-complement Factor C1Q Antibodies And Uses ThereofMay 16, 2023 · US 11,649,279Granted
- METHODS OF DETECTING SYNAPSES COMPRISING ADMINISTERING AN ANTI-C1q ANTIBODYApr 22, 2021 · Application 16843449Pending
- Anti-complement Factor C1Q Antibodies And Uses ThereofFeb 23, 2021 · US 10,927,167Granted
- Anti-complement Factor C1Q Fab Fragments And Uses ThereofJul 28, 2020 · US 10,723,788Granted
- Anti-complement Factor C1Q Antibodies And Uses ThereofMar 17, 2020 · US 10,590,190Granted
- Humanized Anti-complement Factor C1Q Antibodies And Uses ThereofOct 17, 2019 · Application 16415278Pending
- Humanized Anti-complement Factor C1Q AntibodiesJun 11, 2019 · US 10,316,081Granted
- Compositions And Methods For Treating Spinal Muscular AtrophyMay 30, 2019 · Application 16099916Pending
- Anti-complement Factor C4/C4B Antibodies And Uses ThereofMay 23, 2019 · Application 16300207Pending
- Anti-complement Factor C1Q Antibodies And Uses ThereofMar 12, 2019 · US 10,227,398Granted
- Anti-complement Factor C1Q Antibodies And Uses ThereofJul 18, 2017 · US 9,708,394Granted
- Methods For Screening For Inhibitors Of Complement Serine ProteasesMar 23, 2017 · Application 15125367Pending
- Anti-complement Factor C1S Antibodies And Uses ThereofMar 31, 2016 · Application 14890811Pending
- Compositions and Methods for Treating Spinal Muscular AtrophyApplication 62333348Pending
- Anti-Complement Factor C1Q Fab Fragments and Uses ThereofApplication 62259227Pending
- Humanized Anti-complement Factor C1Q Antibodies And Uses ThereofApplication PCTUS2015059185Pending
- Methods For Screening For Inhibitors Of Complement Serine ProteasesApplication PCTUS2015021604Pending
- Humanized Anti-complement Factor C1Q Antibodies And Uses ThereofApplication 62075793Pending
- Anti-complement Factor C1Q Antibodies And Uses ThereofApplication PCTUS2014046042Pending
- Anti-complement Factor C1S Antibodies And Uses ThereofApplication PCTUS2014038239Pending
- Methods For Screening For Inhibitors Of Complement Serine ProteasesApplication 61955742Pending
Recent research by its founders
- An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of <scp>ANX005</scp> in Patients with Huntington's Disease20261 cites
- Targeting C1q prevents microglia-mediated synaptic removal in neuropathic pain202537 cites
- Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of <scp>ANX005</scp>, a C1q Inhibitor, in Patients With Guillain–Barré Syndrome202513 cites
Related companies, and why
- Mulberry Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NUAGO THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- APIE THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- SYNTAXISBIO, INC.Similar federal contract value in Biotech · null in contracts
- EPITOR THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- DFH Pharma, IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .